Nivolumab and ipilimumab (N plus I) is active in patients (pts) with metastatic uveal melanoma (mUM) with extra-hepatic only involvement: Pooled analysis from 2 phase II trials

Piulats Rodriguez, J. M.Patel, S.Espinosa, E.Pelster, M. S.de la Cruz Merino, L.Khoja, L. T.Joshua, A. M.Tebe, C.Berrocal, A.2025-01-072025-01-072020-09-010923-7534https://hdl.handle.net/10668/27551enNivolumab and ipilimumab (N plus I) is active in patients (pts) with metastatic uveal melanoma (mUM) with extra-hepatic only involvement: Pooled analysis from 2 phase II trialsconference outputopen access10.1016/j.annonc.2020.08.12661569-8041http://www.annalsofoncology.org/article/S0923753420412621/pdf573469101430